Mark Elliott Boulding - 02 Sep 2021 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role: Exec. VP and CLO
Signature: /s/ Avraham S. Adler, attorney-in-fact
Issuer symbol: PTCT
Transactions as of: 02 Sep 2021
Net transactions value: -$151,375
Form type: 4
Filing time: 03 Sep 2021, 16:06:07 UTC
Previous filing: 12 Jul 2021
Next filing: 11 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PTCT	Common Stock	Options Exercise	$60,568	+3,363	+7%	$18.01	51,737	02 Sep 2021	Direct	F1
transaction	PTCT	Common Stock	Sale	$151,375	-3,363	-6.5%	$45.01	48,374	02 Sep 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PTCT	Stock Option (Right to Buy)	Options Exercise	$60,568	-3,363	-18%	$18.01	15,653	02 Sep 2021	Common Stock	3,363	$18.01	Direct	F1, F3
holding	PTCT	Stock Option (Right To Buy)						191	02 Sep 2021	Common Stock	191	$218.40	Direct	F4
holding	PTCT	Stock Option (Right To Buy)						85,600	02 Sep 2021	Common Stock	85,600	$51.00	Direct	F4
holding	PTCT	Stock Option (Right To Buy)						70,000	02 Sep 2021	Common Stock	70,000	$30.86	Direct	F4
holding	PTCT	Stock Option (Right to Buy)						4,563	02 Sep 2021	Common Stock	4,563	$11.23	Direct	F4
holding	PTCT	Stock Option (Right To Buy)						72,500	02 Sep 2021	Common Stock	72,500	$33.02	Direct	F5
holding	PTCT	Stock Option (Right To Buy)						17,500	02 Sep 2021	Common Stock	17,500	$33.02	Direct	F6
holding	PTCT	Stock Option (Right To Buy)						59,500	02 Sep 2021	Common Stock	59,500	$51.16	Direct	F7
holding	PTCT	Stock Option (Right to Buy)						59,500	02 Sep 2021	Common Stock	59,500	$66.49	Direct	F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021.
F2	This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.00 to $45.04 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3	This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
F4	Currently exercisable.
F5	This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
F6	This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
F7	This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
F8	This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.